Great to have Chris leading the company he is so experienced with plenty of commitment holding a massive ... 2,527,798 shares
“Dr Burns has over 30 years’ experience in drug discovery and development and has served in executive level positions, including as CEO, for a number of public and private biotechnology companies. Dr Burns’ deep experience in cancer biology and kinase inhibitor development has contributed to advancement of multiple clinical candidates and he was the lead inventor of the drug momelotinib, a Janus kinase (JAK) inhibitor targeting myelofibrosis, which was recently acquired by GSK for US$1.9billion.”
Looking forward to regular updates / video interviews
And a little snippet telling us how the trails are going
Would do the trick nicely ...
.
- Forums
- ASX - By Stock
- ATX
- Ann: Amplia Appoints Dr Christopher Burns CEO & Managing Director
Ann: Amplia Appoints Dr Christopher Burns CEO & Managing Director, page-3
-
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ATX (ASX) to my watchlist
(20min delay)
|
|||||
Last
8.9¢ |
Change
-0.002(2.20%) |
Mkt cap ! $24.95M |
Open | High | Low | Value | Volume |
9.0¢ | 9.0¢ | 8.9¢ | $18.85K | 210K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 33428 | 8.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
9.0¢ | 140000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 33428 | 0.088 |
1 | 29800 | 0.087 |
1 | 15000 | 0.086 |
3 | 244574 | 0.085 |
1 | 5952 | 0.084 |
Price($) | Vol. | No. |
---|---|---|
0.090 | 140000 | 1 |
0.091 | 136558 | 1 |
0.092 | 14158 | 2 |
0.095 | 47952 | 1 |
0.099 | 11000 | 1 |
Last trade - 12.11pm 30/07/2024 (20 minute delay) ? |
Featured News
ATX (ASX) Chart |
The Watchlist
MTL
MANTLE MINERALS LIMITED
Nick Poll, Executive Director
Nick Poll
Executive Director
SPONSORED BY The Market Online